KR20200113237A - 결장암 검출 및 치료 모니터링을 위한 방법 - Google Patents

결장암 검출 및 치료 모니터링을 위한 방법 Download PDF

Info

Publication number
KR20200113237A
KR20200113237A KR1020207024237A KR20207024237A KR20200113237A KR 20200113237 A KR20200113237 A KR 20200113237A KR 1020207024237 A KR1020207024237 A KR 1020207024237A KR 20207024237 A KR20207024237 A KR 20207024237A KR 20200113237 A KR20200113237 A KR 20200113237A
Authority
KR
South Korea
Prior art keywords
score
subject
therapy
expression level
colon cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207024237A
Other languages
English (en)
Korean (ko)
Inventor
마크 키드
이그나트 드로즈도브
어빈 마크 모들린
Original Assignee
리퀴드 바이옵시 리서치 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리퀴드 바이옵시 리서치 엘엘씨 filed Critical 리퀴드 바이옵시 리서치 엘엘씨
Publication of KR20200113237A publication Critical patent/KR20200113237A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioethics (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
KR1020207024237A 2018-01-22 2019-01-22 결장암 검출 및 치료 모니터링을 위한 방법 Ceased KR20200113237A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862620015P 2018-01-22 2018-01-22
US62/620,015 2018-01-22
PCT/US2019/014490 WO2019144099A1 (en) 2018-01-22 2019-01-22 Methods for colon cancer detection and treatment monitoring

Publications (1)

Publication Number Publication Date
KR20200113237A true KR20200113237A (ko) 2020-10-06

Family

ID=65279827

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207024237A Ceased KR20200113237A (ko) 2018-01-22 2019-01-22 결장암 검출 및 치료 모니터링을 위한 방법

Country Status (15)

Country Link
US (3) US11414707B2 (https=)
EP (1) EP3743534B1 (https=)
JP (1) JP7297770B2 (https=)
KR (1) KR20200113237A (https=)
CN (1) CN112004945B (https=)
AU (1) AU2019209436B2 (https=)
BR (1) BR112020014737A2 (https=)
CA (1) CA3088754A1 (https=)
DK (1) DK3743534T3 (https=)
ES (1) ES2917629T3 (https=)
IL (1) IL276089B2 (https=)
MX (1) MX2020007771A (https=)
PL (1) PL3743534T3 (https=)
SG (1) SG11202006974WA (https=)
WO (1) WO2019144099A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230054210A (ko) * 2021-10-15 2023-04-24 한국과학기술원 인공지능을 이용하여 유전체 염기서열로 질환 진단 및 예측 방법, 그 시스템

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3743534T3 (pl) 2018-01-22 2022-09-05 Liquid Biopsy Research LLC Sposoby wykrywania nowotworu okrężnicy i monitorowania leczenia
MX2022004372A (es) 2019-10-10 2022-07-27 Liquid Biopsy Res Llc Composiciones, métodos y kits para la estabilización de muestras biológicas y de arn.
US11809379B2 (en) * 2019-11-19 2023-11-07 International Business Machines Corporation Storage tiering for deduplicated storage environments
CN111157745A (zh) * 2020-01-17 2020-05-15 上海交通大学 人snrpa蛋白在肺癌复发或转移监测中的用途
CN115475247B (zh) * 2021-06-16 2024-02-20 厦门大学 β2-微球蛋白或其抑制剂的制药用途
CN113921079B (zh) * 2021-12-06 2022-03-18 四川省肿瘤医院 基于免疫相关基因的msi预测模型构建方法
CN121137146B (zh) * 2025-07-28 2026-04-07 首钢医院有限公司 检测基因组合物的试剂在制备预测结直肠癌患者远端切缘长度的产品中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2169077A1 (en) * 2008-09-19 2010-03-31 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Methods and compositions for diagnosing an adenocarcinoma
EP2169078A1 (en) 2008-09-26 2010-03-31 Fundacion Gaiker Methods and kits for the diagnosis and the staging of colorectal cancer
KR101051435B1 (ko) * 2008-10-22 2011-07-22 한국생명공학연구원 대장암 관련 마커를 이용한 대장암 진단 키트 및 이를 이용한 대장암 진단 방법
KR101073875B1 (ko) 2008-11-28 2011-10-14 한국생명공학연구원 대장암 진단 마커 및 이를 이용한 대장암 진단방법
SG10201401722XA (en) 2009-05-01 2014-08-28 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer andresponse to chemotherapy
EP2309002A1 (en) * 2009-09-29 2011-04-13 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of colorectal cancer aggressiveness
ES2525382T3 (es) * 2010-03-31 2014-12-23 Sividon Diagnostics Gmbh Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino
EP2426216A1 (en) * 2010-09-01 2012-03-07 Institut Gustave Roussy (IGR) Prognostic and/or predictive biomarkers and biological applications thereof
CN103403187A (zh) 2011-01-18 2013-11-20 艾沃锐斯特基因有限公司 结肠直肠癌复发的预后特征
JP2014509189A (ja) 2011-01-25 2014-04-17 アルマック ダイアグノスティックス リミテッド 結腸ガン遺伝子発現シグネチャーおよび使用方法
US20150226744A1 (en) * 2012-09-17 2015-08-13 Ait Austrian Institute Of Technology Gmbh Colon Cancer Diagnostic Method and Means
WO2014085826A2 (en) * 2012-11-30 2014-06-05 Applied Proteomics, Inc. Method for evaluation of presence of or risk of colon tumors
EP2985296A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
PL3743534T3 (pl) 2018-01-22 2022-09-05 Liquid Biopsy Research LLC Sposoby wykrywania nowotworu okrężnicy i monitorowania leczenia

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230054210A (ko) * 2021-10-15 2023-04-24 한국과학기술원 인공지능을 이용하여 유전체 염기서열로 질환 진단 및 예측 방법, 그 시스템

Also Published As

Publication number Publication date
CA3088754A1 (en) 2019-07-25
JP2021511057A (ja) 2021-05-06
EP3743534A1 (en) 2020-12-02
SG11202006974WA (en) 2020-08-28
IL276089A (en) 2020-08-31
IL276089B2 (en) 2024-07-01
AU2019209436B2 (en) 2025-06-05
AU2019209436A1 (en) 2020-08-06
DK3743534T3 (da) 2022-06-20
CN112004945A (zh) 2020-11-27
EP3743534B1 (en) 2022-03-23
US20230220482A1 (en) 2023-07-13
PL3743534T3 (pl) 2022-09-05
WO2019144099A1 (en) 2019-07-25
MX2020007771A (es) 2020-09-03
IL276089B1 (en) 2024-03-01
US20250243553A1 (en) 2025-07-31
BR112020014737A2 (pt) 2020-12-08
JP7297770B2 (ja) 2023-06-26
US20190226030A1 (en) 2019-07-25
US11414707B2 (en) 2022-08-16
ES2917629T3 (es) 2022-07-11
CN112004945B (zh) 2025-02-14
US12305240B2 (en) 2025-05-20

Similar Documents

Publication Publication Date Title
AU2019209436B2 (en) Methods for colon cancer detection and treatment monitoring
AU2019201577B2 (en) Cancer diagnostics using biomarkers
KR102921718B1 (ko) 전립선암 검출 및 치료 방법
KR101545020B1 (ko) 식도암 및 식도암 전이 진단을 위한 조성물 및 방법
KR20220094218A (ko) 핵산 분자의 분석 방법 및 시스템
AU2017343779A1 (en) Compositions and methods for predicting response and resistance to CTLA4 blockade in melanoma using a gene expression signature
KR20240005018A (ko) 핵산 분자를 분석하기 위한 방법 및 시스템
KR102842664B1 (ko) 유전자 발현 검정을 이용한 펩티드 수용체 방사선요법의 예측
US12478665B2 (en) Cancer vaccine compositions and methods for using same to prevent and/or treat cancer
KR20070099564A (ko) 급성 골수성 백혈병 환자를 평가하는 방법
WO2002064611A1 (en) Compositions and methods relating to breast specific genes and proteins
US20030175715A1 (en) Compositions and methods relating to breast specific genes and proteins
US20020192220A1 (en) Compositions and methods relating to colon specific genes and proteins
US20020192666A1 (en) Compositions and methods relating to colon specific genes and proteins
HK40060652A (en) Methods and systems for analyzing nucleic acid molecules
CN117580963A (zh) 用于分析核酸分子的方法和系统
HK40042084B (en) Methods for colon cancer detection and treatment monitoring
HK40042084A (en) Methods for colon cancer detection and treatment monitoring
KR20220122197A (ko) 비근침윤성 방광암의 예후 예측을 위한 바이오마커 및 이의 용도
KR20110036560A (ko) 대장암 진단용 조성물 및 그 용도
HK40043345A (en) Methods for prostate cancer detection and treatment
HK40043345B (en) Methods for prostate cancer detection and treatment
WO2005044075A2 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
KR20110036561A (ko) 대장암 진단용 조성물 및 그 용도

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000